Physician profile
Amit K Seth
NPI 1316196165
$44,356.51
in general payments reported to CMS, 2019-2025
40 companies · $3,296 in 2025
The $3,296 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $17K · 2021: $9,349 · 2022: $1,551 · 2023: $1,529 · 2024: $1,234 · 2025: $3,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,908 · Travel and Lodging: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,908.17 |
| Travel and Lodging | $1,151.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35,578.76 | 2019-2025 | Farxiga |
| Medtronic, INC. | $1,837.97 | 2021-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $1,226.10 | 2019 | |
| Abbott Laboratories | $747.59 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $620.25 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.48 | 2021-2025 | Jardiance |
| Amgen INC. | $385.99 | 2019-2025 | Tepezza, Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $366.69 | 2020-2025 | Unithroid |
| Sanofi-Aventis U.S. LLC | $359.32 | 2020-2025 | |
| Dexcom, INC. | $357.51 | 2021-2023 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $312.79 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $274.53 | 2020-2025 | |
| Xeris Pharmaceuticals, INC. | $251.71 | 2022-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $244.85 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $242.34 | 2022-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $191.08 | 2023-2025 | Omnipod |
| Cequr Corporation | $153.58 | 2021-2025 | Cequr Simplicity |
| Corcept Therapeutics | $112.99 | 2024-2025 | Korlym |
| La Jolla Pharmaceutical Company | $97.05 | 2025 | Giapreza |
| Alexion Pharmaceuticals, INC. | $65.91 | 2024-2025 | Strensiq |
| Horizon Therapeutics Plc | $58.68 | 2022-2023 | Tepezza |
| Exact Sciences Corporation | $43.93 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $33.18 | 2022-2025 | Shingrix |
| Mannkind Corporation | $32.83 | 2025 | |
| Ucb, INC. | $31.43 | 2024-2025 | Bimzelx |
| Merck Sharp & Dohme LLC | $29.98 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $29.62 | 2023-2025 | Isturisa, Signifor Lar |
| Ibsa Pharma INC. | $26.47 | 2022-2023 | Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $24.68 | 2025 | |
| Averitas Pharma INC. | $23.57 | 2025 | Qutenza |
| Bigfoot Biomedical INC | $23.45 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.02 | 2023 | Cycloset |
| Tactile Systems Technology INC | $18.61 | 2023 | Entre Plus, Flexitouch Plus |
| Madrigal Pharmaceuticals | $17.99 | 2025 | Rezdiffra |
| Sequel Med Tech, LLC | $17.92 | 2025 | Twiist |
| Echosens North America, INC. | $17.41 | 2024 | Fibroscan |
| Incyte Corporation | $16.46 | 2024 | Opzelura |
| Becton, Dickinson and Company | $16.16 | 2022 | |
| Amryt Pharma Holdings LTD | $15.71 | 2023 | Mycapssa |
| Embecta Corp. | $12.92 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.